Kainos Laboratories, Inc. (4556) AI Stock Analysis

• Market Cap: ¥9.35B
• Dividend Yield: 2.53%
• Average Volume (3M): 3.67K
• Price to Earnings (P/E): 9.5
• Beta (1Y): 0.53
• Revenue Growth: 3.14%
• EPS Growth: -2.85%
• Country: JP
• Employees: 133
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 105.98
• Shares Outstanding: 4,558,860
• 10 Day Avg. Volume: 3,280
• 30 Day Avg. Volume: 3,666
• PEG Ratio: -62.73
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 1.00
• P/FCF Ratio: 8.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 85 Outperform
• Price Target: ¥2,684.00 ▲(111.17% Upside)
• Action: Upgraded Date: 02/10/26
• Date: Action: Upgraded 02/10/26

The score is driven primarily by strong financial performance (profitability, low leverage, and especially strong free cash flow growth) and an attractive valuation (low P/E with a solid dividend yield). Technicals are supportive due to a strong uptrend, but the very high RSI suggests the stock may be overextended in the near term, moderating the overall score.

Positive Factors

Strong free cash flow

Very strong free cash flow growth and nearly 1:1 conversion of net income to FCF provide durable internal funding for capex, R&D and dividends. High cash conversion reduces reliance on external financing and supports long-term strategic initiatives and resilience.

Conservative balance sheet

Extremely low leverage and a high equity ratio give the company financial flexibility to withstand shocks, fund investments or pursue opportunistic M&A. Low interest burden preserves margins and reduces refinancing risk over the medium term.

High profitability margins

Robust gross and EBITDA margins indicate pricing power and operational efficiency in its diagnostics business. Sustained margins support free cash generation and reinvestment capacity, creating a durable earnings base resilient to moderate cost pressures.

Negative Factors

Modest revenue growth

Single-digit top-line growth limits the company’s ability to scale and leverage fixed costs. In a competitive, innovation-driven diagnostics market, modest revenue expansion can restrain market-share gains and cap long-run earnings and investment capacity.

Limited scale / small workforce

A small employee base and limited scale may constrain R&D throughput, commercial distribution and customer support versus larger rivals. Reduced scale can slow product rollouts and make it harder to compete for large institutional contracts long-term.

Concentration in diagnostics reagents

Concentration in in-vitro diagnostics and reagent products leaves revenue exposed to regulatory approval cycles, reimbursement policy changes and pricing pressure. Product concentration raises structural risk to margins and growth if market or regulatory dynamics shift.

Kainos Laboratories, Inc. Business Overview & Revenue Model

Company Description

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.

How the Company Makes Money

null

Kainos Laboratories, Inc. Financial Statement Overview

Summary

Strong fundamentals across statements: solid profitability (gross margin 49.28%, net margin 12.08%) and healthy operating efficiency (EBITDA margin 17.66%). Balance sheet is conservative (debt-to-equity 0.09; equity ratio 77.12%). Cash generation is a standout with free cash flow growth of 78.44% and good earnings-to-cash conversion (OCF/NI 1.10; FCF/NI 0.99).

Income Statement

Kainos Laboratories has demonstrated consistent revenue growth with a Revenue Growth Rate of 4.93% from 2024 to 2025. The Gross Profit Margin is 49.28% for 2025, indicating strong profitability. The Net Profit Margin has improved to 12.08%, reflecting efficient cost management. EBIT and EBITDA margins are robust at 15.52% and 17.66%, respectively, highlighting the company's operational efficiency.

Balance Sheet

The company maintains a strong financial position with a low Debt-to-Equity Ratio of 0.09, indicating conservative leverage. The Equity Ratio is high at 77.12%, showing a strong capital structure. Return on Equity (ROE) is healthy at 9.46%, reflecting effective use of equity capital to generate profits.

Cash Flow

Kainos Laboratories exhibits strong cash flow performance with a Free Cash Flow Growth Rate of 78.44% from 2024 to 2025. The Operating Cash Flow to Net Income Ratio is favorable at 1.10. The Free Cash Flow to Net Income Ratio stands at 0.99, indicating efficient conversion of earnings into free cash flow.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	5.31B	5.06B	4.92B	4.61B	4.26B
Gross Profit	2.61B	2.48B	2.45B	2.35B	2.25B
EBITDA	919.48M	977.00M	956.45M	897.86M	775.07M
Net Income	641.02M	637.97M	568.17M	512.33M	417.40M
Balance Sheet
Total Assets	8.83B	8.61B	8.12B	7.57B	6.96B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.17B	3.02B	2.68B	2.24B
Total Debt	629.49M	862.97M	941.10M	947.61M	1.00B
Total Liabilities	2.06B	2.34B	2.45B	2.37B	2.30B
Stockholders Equity	6.78B	6.27B	5.67B	5.20B	4.66B
Cash Flow
Free Cash Flow	633.30M	356.87M	536.81M	463.19M	518.06M
Operating Cash Flow	704.78M	430.58M	544.51M	604.36M	591.25M
Investing Cash Flow	-71.30M	-72.83M	-10.33M	-141.19M	-117.16M
Financing Cash Flow	-411.04M	-203.73M	-191.14M	-31.25M	-194.61M

Kainos Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1271.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1271 is below the 20-day moving average (MA) of 2279.00, below the 50-day MA of 1853.60, and below the 200-day MA of 1409.31, indicating a bullish trend. The MACD of 106.70 indicates Positive momentum. The RSI at 93.94 is Negative, neither overbought nor oversold. The STOCH value of 76.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.

Kainos Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4556	85 Outperform	¥9.35B	9.53	―	2.53%	3.14%	-2.85%
6869	71 Outperform	¥863.70B	16.38	9.38%	1.88%	1.51%	-12.59%
7747	68 Neutral	¥836.83B	24.33	11.64%	0.82%	13.53%	-7.39%
4543	67 Neutral	¥3.01T	25.64	8.98%	1.22%	7.68%	10.08%
8086	62 Neutral	¥242.36B	5.59	4.38%	2.03%	6.04%	733.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%